5-FU: 5-Fluorouracil; ECOG: Eastern Cooperative Oncology Group; EXTREME: Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer; LA: Locoregionally advanced; LC: Median ...

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone Preclinical studies demonstrated ...

Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the ...

The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab ...

A study found that cetuximab along or with chemotherapy was an effective option in patients with metastatic colorectal cancer (CRC). Patients with metastatic colorectal cancer (mCRC) could be ...

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum-containing ...

Cetuximab is a monoclonal antibody that specifically inhibits the epidermal growth factor receptor (EGFR). EGFR is a transmembrane glycoprotein that is a member of the ErbB family of receptors which ...

November 7, 2011 — The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and ...

The FDA approved encorafenib, cetuximab, and mFOLFOX6 for mCRC with BRAF V600E mutation, based on the BREAKWATER trial results. The trial showed a 61% ORR for the combination therapy, compared to 40% ...

Expression of the Caudal-Type Homeodomain Transcription Factors CDX 1/2 and Outcome in Carcinomas of the Ampulla of Vater Pharmacy computer records were reviewed to identify all patients who received ...

Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR) which is present on the surface of some cancer cells. Cetuximab binds to the receptor, preventing epidermal ...

Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now ...